Skip to main content
logo
Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
28.42
-1.31 (-4.41%)
At close: Jul 24, 2026, 4:00 PM EDT
28.42
0.00 (0.00%)
After-hours: Jul 24, 2026, 6:30 PM EDT

Arcus Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
236247258117112383
Revenue Growth (YoY)
67.38%-4.26%120.51%4.46%-70.76%391.03%
Gross Profit
236247258117112383
Selling, General & Admin
11111012011710472
Research & Development
523523448340288257
Other Operating Expenses
--20---
Total Operating Expenses
634633588457392329
Operating Income
-398-386-330-340-28054
Interest Income
39415241161
Interest Expense
-10-8-4-2-2-
Total Non-Operating Income (Expense)
29334839141
Pretax Income
-369-353-282-301-26655
Provision for Income Taxes
--1612
Net Income
-369-353-283-307-26753
Net Income to Common
-369-353-283-307-26753
Shares Outstanding (Basic)
11410790747269
Shares Outstanding (Diluted)
11410790747274
Shares Change (YoY)
22.63%19.20%21.76%2.78%-2.70%35.04%
EPS (Basic)
-3.23-3.29-3.14-4.15-3.710.76
EPS (Diluted)
-3.23-3.29-3.14-4.15-3.710.71
Free Cash Flow
-489-484-176-330432-282
Free Cash Flow Per Share
-4.28-4.51-1.95-4.466.00-3.81
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-168.64%-156.28%-127.91%-290.60%-250.00%14.10%
Profit Margin
-156.36%-142.91%-109.69%-262.39%-238.39%13.84%
FCF Margin
-207.20%-195.95%-68.22%-282.05%385.71%-73.63%
EBITDA
-389-376-320-332-27458
EBITDA Margin
-164.83%-152.23%-124.03%-283.76%-244.64%15.14%
EBIT
-398-386-330-340-28054
EBIT Margin
-168.64%-156.28%-127.91%-290.60%-250.00%14.10%
Effective Tax Rate
-0.00%-0.35%-1.99%-0.38%3.64%
SEC Filings: 10-K · 10-Q